Payment overview · 2025
General Payments
$443.20
14 reported records · 10 companies
Healthcare provider profile · identity verified
Mohammad S Bahrami, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MUNCIE, IN · NPI 1083791719
Verified facts
What the public records show
CMS Open Payments records show Mohammad S Bahrami, MD received $443.20 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 411 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.79 | 32.2% | 3 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $94.62 | 21.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.93 | 11.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.78 | 10.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.06 | 6.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 4.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.45 | 4.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.22 | 3.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.97 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.53 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $424.35 | 13 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.45 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.93 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 411 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
38 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
411 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2406 | 228 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1852 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 1283 | 127 |
| Lisinopril | Lisinopril | 1050 | 117 |
| Furosemide | Furosemide | 907 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 895 | 112 |
| Potassium Chloride | Potassium Chloride | 850 | 89 |
| Gabapentin | Gabapentin | 756 | 91 |
| Metformin Hcl | Metformin Hcl | 676 | 97 |
| Carvedilol | Carvedilol | 622 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 595 | 65 |
| Sertraline Hcl | Sertraline Hcl | 593 | 52 |
| Donepezil Hcl | Donepezil Hcl | 590 | 59 |
| Mirtazapine | Mirtazapine | 518 | 61 |
| Levetiracetam | Levetiracetam | 484 | 26 |
| Trazodone Hcl | Trazodone Hcl | 466 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 444 | 71 |
| Divalproex Sodium | Divalproex Sodium | 431 | 34 |
| Eliquis | Apixaban | 411 | 51 |
| Buspirone Hcl | Buspirone Hcl | 409 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 403 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 397 | 44 |
| Torsemide | Torsemide | 365 | 22 |
| Olanzapine | Olanzapine | 361 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 332 | 58 |
| Allopurinol | Allopurinol | 327 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 325 | 50 |
| Losartan Potassium | Losartan Potassium | 312 | 34 |
| Tramadol Hcl | Tramadol Hcl | 277 | 55 |
| Memantine Hcl | Memantine Hcl | 274 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 258 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 255 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 254 | 63 |
| Omeprazole | Omeprazole | 249 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 236 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 227 | 35 |
| Meloxicam | Meloxicam | 227 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 217 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 26 |
| Bupropion Xl | Bupropion Hcl | 197 | 23 |
| Montelukast Sodium | Montelukast Sodium | 196 | 36 |
| Topiramate | Topiramate | 193 | 18 |
| Famotidine | Famotidine | 167 | 22 |
| Spironolactone | Spironolactone | 152 | 13 |
| Simvastatin | Simvastatin | 149 | 25 |
| Risperidone | Risperidone | 148 | 18 |
| Xarelto | Rivaroxaban | 145 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 138 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 128 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 53 |
| Prednisone | Prednisone | 122 | 73 |
| Ondansetron Hcl | Ondansetron Hcl | 116 | 39 |
| Myrbetriq | Mirabegron | 109 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 43 |
| Warfarin Sodium | Warfarin Sodium | 99 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 21 |
| Baclofen | Baclofen | 86 | 15 |
| Farxiga | Dapagliflozin Propanediol | 85 | 19 |
| Midodrine Hcl | Midodrine Hcl | 85 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 82 | 26 |
| Propranolol Hcl | Propranolol Hcl | 80 | suppressed |
| Ezetimibe | Ezetimibe | 79 | 13 |
| Pregabalin | Pregabalin | 78 | 11 |
| Azithromycin | Azithromycin | 77 | 58 |
| Trulicity | Dulaglutide | 77 | 14 |
| Latanoprost | Latanoprost | 75 | 13 |
| Alendronate Sodium | Alendronate Sodium | 74 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 73 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 11 |
| Jardiance | Empagliflozin | 70 | suppressed |
| Primidone | Primidone | 70 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 14 |
| Loperamide | Loperamide Hcl | 69 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 34 |
| Benztropine Mesylate | Benztropine Mesylate | 68 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 46 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 65 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 64 | suppressed |
| Alprazolam | Alprazolam | 63 | suppressed |
| Nystatin | Nystatin | 61 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 40 |
| Clonidine Hcl | Clonidine Hcl | 59 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 58 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 57 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Aripiprazole | Aripiprazole | 55 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 54 | suppressed |
| Cephalexin | Cephalexin | 53 | 43 |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 52 | suppressed |
| Tradjenta | Linagliptin | 50 | suppressed |
| Atenolol | Atenolol | 49 | 11 |
| Carbamazepine | Carbamazepine | 49 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 27 |
| Levofloxacin | Levofloxacin | 45 | 36 |
| Ibuprofen | Ibuprofen | 43 | 20 |
| Linzess | Linaclotide | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 20 |
| Nortriptyline Hcl | Nortriptyline Hcl | 42 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 42 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 41 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 30 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Nyamyc | Nystatin | 35 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 33 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | 13 |
| Synthroid | Levothyroxine Sodium | 31 | 11 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 25 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 25 | 17 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 25 | suppressed |
| Haloperidol | Haloperidol | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 15 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Nexium | Esomeprazole Magnesium | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 11 |
| Valsartan | Valsartan | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 18 |
| Ondansetron Odt | Ondansetron | 20 | 15 |
| Xifaxan | Rifaximin | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Itraconazole | Itraconazole | 17 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 17 | 13 |
| Moxifloxacin | Moxifloxacin Hcl | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Theo-24 | Theophylline Anhydrous | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | 11 |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | 11 |
| Ibu | Ibuprofen | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $443.20 · 14 records | Novo Nordisk Inc | AIRSUPRA, BEXSERO, Cologuard Collection Kit, ELIQUIS, JARDIANCE, NURTEC ODT, OPTIS, Ozempic, PEDIARIX, ROTARIX, VENASEAL, WATCHMAN FLX | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error